{"id":"nbp607-v","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL380352","moleculeType":"Small molecule","molecularWeight":"584.76"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NBP607-V binds to GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion while simultaneously suppressing glucagon release. The fusion with human albumin extends the drug's half-life, allowing for less frequent dosing. This mechanism addresses both fasting and postprandial hyperglycemia in type 2 diabetes.","oneSentence":"NBP607-V is a recombinant human albumin-fused glucagon-like peptide-1 (GLP-1) receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:39.882Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02467842","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-10","conditions":"Influenza","enrollment":1503}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NBP607-V","genericName":"NBP607-V","companyName":"SK Chemicals Co., Ltd.","companyId":"sk-chemicals-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"NBP607-V is a small molecule intervention being studied for its effects on influenza. It is part of a quadrivalent influenza vaccine, specifically NBP607-QIV, which is being tested for immunogenicity and safety in adults and elderly subjects.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}